WADA 2010 Prohibited List Now Published

On the last day of the USAS Convention, the Executive committee of the World Anti-Doping Agency (WADA) approved the 2010 Prohibited Substances and Methods List. The United States Anit-Doping Agency (USADA) will review these changes and rules on January 1, 2010. Read below for the major changes and publish their list in the coming weeks. For the full 2010 list use the link at the bottom of this article. The following was posted to the WADA website on September 30, 2009

Title: WADA 2010 Prohibited List Now Published

Date: September 30, 2009

Following its approval by WADA's Executive Committee on September 19, the 2010 List of Prohibited Substances and Methods is now available. This List will go into effect on January 1, 2010.

The 2010 List reflects the latest scientific advances and offers a number of noteworthy changes compared to the 2009 List:

Salbutamol
The status of salbutamol, a beta-2 agonist, will change. Therapeutic use of inhaled salbutamol will not be prohibited as of January 1, 2010. If the urinary concentration is above 1,000 nanograms per millilitre, there will be a presumption that the substance was not taken by inhalation and the athlete will have the burden to demonstrate through a controlled pharmacokinetic study that the level found in his urine was the result of therapeutic inhaled use.

T/E Ratio Follow-Up
No further collections or analyses will be required in cases where the testosterone to epitestosterone (T/E) ratio is greater than 4 and an isotope ratio mass spectrometry (IRMS) test or any other reliable analytical method has not revealed evidence of exogenous administration of a prohibited substance.

Pseudoephedrine
Pseudoephedrine will be reintroduced to the List and will be prohibited above 150 micrograms per millilitre.

To consult the 2010 List, the 2010 Monitoring Program, a summary of modifications, a document providing additional information in regards to the reintroduction of pseudoephedrine, as well as a Q&A on major changes, click here.